17 November 2026 | Tuesday | Interaction
Image Source: Public Domain
Inherited retinal diseases such as Usher syndrome and Stargardt disease remain difficult to treat, particularly when the genes involved are too large for conventional gene therapy delivery systems. AAVantgarde is advancing its dual-AAV platform through the Phase 1/2 LUCE-1 and CELESTE studies, with early clinical findings and ongoing research supporting further development. BioPharma Boardroom speaks with Natalia Misciatelli, CEO, AAVantgarde about its clinical progress, the potential of dual-AAV technology and the next milestones in developing gene therapies for inherited retinal diseases.
Q: With LUCE-1 now fully enrolled and early signals of visual improvement emerging, what do these data tell you about the potential of AAVB-081, and what will you be looking for as follow-up matures?
We are very excited about the LUCE-1 dataset maturing and what we’ve seen so far in the Phase 1/2 study. We’ve been actively sharing our data with the ophthalmology community and more broadly, to make sure everyone has a chance to learn from us and watch as we become the first dual-AAV company to take a program into the clinic. In the dataset we are seeing a clear efficacy signal, and we will be publishing our findings from the fully mature Phase 1/2 study in the coming months.
Q: AAVantgarde’s dual-AAV approach is designed to address genes that are too large for conventional single AAV vectors. How could this capability expand the range of inherited retinal diseases that are addressable with gene therapy?
AAVantgarde’s platform technologies are designed for driving maximum efficacy. We have developed two separate, propietary technologies, both focused on delivering oversized genes - which means genes that don’t fit into a standard AAV cassette capsid- for maximum impact for our future patients. Our two programs in the clinic were brought forward with this concept in mind, and both have shown high efficacy in preclinical data. In our first program, we are starting to see that borne out in the clinic. Looking ahead, there are other genes that are oversized for a standard AAV cassettecapsid, both in inherited retinal diseases and outside of them, where our platform technology can be applied, as it is gene and capsid agnostic.
Q: For AAVB-039 in Stargardt disease, what gives you confidence that the preclinical findings can translate into meaningful clinical benefit, and what will be the key measures of success in the CELESTE study?
This is our second program, and as with our first, we have done extensive preclinical work. We are the only company to have published large animal data in Science showing the high efficacy of our technology. We have shown that our platform technology can normalize gene expression and is safe in knockout pigs. We have also shown safety and efficacy an effect in non-human primates, along with a wide range of other work on safety in smaller and larger animals.
We are currently enrolling subjects into our Phase 1/2 clinical stydy the program into the clinic and expect to complete enrolment by the end of this year. The key measure of success for our Phase 1/2 study will be safety, but we will also be evaluating a variety of endpoints to determine efficacy signals and also the final endpoint for our pivotal study.
Q: The STELLA natural history study has enrolled 150 patients. How will those data support the development of AAVB-039, particularly around patient selection, endpoints and interpretation of clinical outcomes?
We are delighted to have enrolled a 150-patient natural history study. It gives us a whole arsenal of opportunities: understanding disease progression better, understanding the patient population and its variability (phenotypes) better, and understanding, with modern technology and modern measurements, what the right endpoint should be going forward. The study is fully enrolled and the dataset is maturing. We will be publishing data from it to share with the community, driving the science forward while ensuring we are at the cutting edge of research in Stargardt disease.
Q: There is growing industry interest in genetic medicines for inherited retinal diseases. How do you see AAVantgarde’s dual-AAV platform differentiating itself within this increasingly active development landscape?
We are delighted to see the increase interest in genetic medicines in general, not just in inherited retinal diseases but more broadly. For inherited retinal diseases, where we know exactly which gene is causing the issue in patients, genetic medicines and AAVs offer the opportunity to treat the root cause of the disease, which makes this a very exciting modality.
What differentiates us from other gene therapy players is that we can treat diseases that are due to mutations in genes that are oversized for the AAV cassette capsid, and do so in an entirely novel way. We are focusing on those diseases, many of which have no treatment. Stargardt and Usher 1B are just two examples which both involve very large genes. Within the area of diseases with large genes, we are always looking to treat the root cause of the disease rather than tangential factors, and we are always looking for the maximum impact of our product, which means high expression. It means we are looking to normalize, which is what we have shown in our preclinical data, and we hope this will bear out in the clinic.
Q: With two lead programs now advancing clinically, what are the most important milestones ahead for AAVantgarde, and how could progress in Usher syndrome and Stargardt disease support broader development of the dual-AAV platform?
Our Usher program is well and truly maturing, and we are at the cusp of presenting our full dataset for Phase 1/2. At the moment it is looking extremely positive. And for Stargardt, we will share our data as it matures.
As for how the two programs interconnect, they are both based on dual-AAV and both use the same capsid, so there are many learnings between them that we can apply. These include how to manage the immune system and how to ensure we have the right capabilities and support in place to drive high-quality programs forward. It has been a privilege to do so and we hope to carry these technologies beyond the eye.
© 2026 Biopharma Boardroom. All Rights Reserved.